Nutritional compositions for improving cell membranes

By using phospholipid-coated large lipid microspheres in infant formula, increasing palmitic acid at the sn-2 position of triglycerides, and combining with a specific fatty acid ratio, the fatty acid composition of infant cell membranes is improved, addressing the shortcomings of existing infant formulas in brain development and cognitive function, and achieving long-term brain function enhancement and disease prevention effects.

CN123100711APending Publication Date: 2026-11-17NV NUTRICIA
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
CN202611376574.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-03-30
Filing Date
2017-12-08
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing infant formulas cannot effectively mimic the long-chain polyunsaturated fatty acid (LC-PUFA) composition of breast milk in terms of nutrition, resulting in gaps in brain development and cognitive function between breastfed and breastfed infants. Furthermore, the long-term effects of the fatty acid composition of existing infant formulas on brain function have not received sufficient attention.

Method used

A nutritional composition comprising phospholipid-coated large lipid globules is provided, the lipid globules having increased palmitic acid levels at the sn-2 position of triglycerides and containing specific proportions of α-linolenic acid, linoleic acid, palmitic acid and phospholipids, the diameter of the lipid globules being within a specific range, for improving the fatty acid composition of cell membranes.

Benefits of technology

It significantly increased the content of LC-PUFA in the cell membrane, improved the structure and function of the meninges, resulting in improved cognitive function and neurodevelopment. The effects can last into adulthood and it is suitable for the prevention and treatment of diseases related to the fatty acid composition of damaged meninges.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_10
    Figure SMS_10
  • Figure SMS_14
    Figure SMS_14
Patent Text Reader

Abstract

It has been found that nutritional interventions using lipid fractions in early life improve the fatty acid composition of cell membranes (particularly the meninges), said lipid fractions containing large lipid globules of phospholipids and an increased amount of palmitic acid at the sn-2 position of triglycerides.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese invention patent application filed on December 8, 2017, with application number 201780082222.4 and entitled "Nutritional Composition for Improving Cell Membranes". Technical Field

[0002] This invention relates to the field of infant nutrition, and specifically to its effects on brain development. Background Technology

[0003] Breastfeeding is the preferred method of feeding infants. However, there are situations where breastfeeding is not feasible or less than ideal. In these cases, infant formula is a good alternative. The composition of modern infant formula has been adapted to meet the many specific nutritional needs of rapidly growing and developing infants.

[0004] It appears that the composition of infant formula can still be improved. Early nutrients provided during specific periods of infancy during rapid brain growth and development have a programming effect and therefore long-term consequences for brain function. Breastfed infants score better on visual and developmental tests and exhibit improved neurodevelopment compared to formula-fed infants. In particular, long-chain polyunsaturated fatty acids (LC-PUFAs) in human milk, such as docosahexaenoic acid (DHA), make a significant contribution to brain and cognitive and visual development. Breastfed infants have higher DHA concentrations in their brains compared to formula-fed infants. This contributes to enhanced cognitive development, which appears to continue into adulthood. Recent clinical studies in infants have shown that DHA supplementation can improve cognitive function in formula-fed infants. Therefore, the differences in neurodevelopment between breastfed and bottle-fed infants have been primarily attributed to the presence of long-chain polyunsaturated fatty acids (LC-PUFAs) such as docosahexaenoic acid (DHA) and arachidonic acid (ARA) in breast milk. Therefore, most existing infant formulas still contain this type of LC-PUFA. It has also been found that when this type of LC-PUFA is present in the diet as phospholipids rather than triglycerides, it is better incorporated into the membrane.

[0005] WO2009 / 057121 discloses a method for improving, promoting, or maintaining the development of the brain and retina in an infant, the method comprising administering a composition comprising at least one triglyceride, at least one phospholipid, and at least one long-chain polyunsaturated fatty acid (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated with the at least one phospholipid.

[0006] The effects of milk fats and polar lipids derived from cow's milk on brain function have attracted attention. WO 2009 / 051502 discloses the use of one or more complex lipids derived from cow's milk containing gangliosides for maintaining or enhancing cognitive development in fetal, infant, or pediatric subjects.

[0007] WO 2009 / 138680 discloses that the presence of at least 30% dairy fat along with vegetable oil in infant formula can be used, for example, to increase the accumulation of endogenous DHA in the meninges and improve brain development and cognitive function. WO 2008 / 005033 discloses an infant formula for accelerating brain development, neural migration, and cognitive development in infants, comprising gangliosides, phospholipids, sialic acid, docosahexaenoic acid, and arachidonic acid. In all cases, direct dietary effects are disclosed, but longer-term effects are not mentioned. WO 2013 / 153071 discloses a tested infant formula containing sialic acid, cholesterol, sphingomyelin, and having a lower calorie and lower protein content than a control formula. Improved cognitive function has been observed in infants who consumed the experimental formula at 12 months of age.

[0008] WO 2011 / 115476 and WO 2011 / 115491 disclose infant nutrients containing phospholipid-coated lipid globules for improving membrane fatty acid composition and cognitive or behavioral performance. WO2016 / 024864 discloses an infant nutrient containing phospholipid-coated lipid globules for improving behavior.

[0009] WO 2005 / 051091 discloses a lipid formulation which is itself included as a beneficial ingredient in infant formula and is specifically designed to improve cognitive and visual development. It is naturally present in the globular microstructures of human milk. Summary of the Invention

[0010] The inventors, using animal models, discovered a synergistic improvement in the fatty acid composition of the meninges in mice that had consumed a composition early in life comprising large lipid globules coated with phospholipids and increased levels of palmitic acid at the sn-2 position of triglycerides. Compared to control mice, the levels of PUFA, LC-PUFA, and the major single fatty acid components in the meninges (docosahexaenoic acid (DHA) and arachidonic acid (ARA)) were statistically significantly increased. This increase was also greater than that predicted by interventions based solely on compositions containing large lipid globules coated with phospholipids or compositions containing palmitic acid-rich components at the sn-2 position of triglycerides. Therefore, this represents a typical synergistic improvement in cell membrane composition, particularly the meningeal composition, and an increase in cell membrane fluidity. This meningeal structural effect is associated with improved brain function, and thus indicates improvements in brain function, particularly cognitive function. In particular, it suggests that this effect will persist into later life. In a clinical trial, compared with infants consuming standard infant formula, the fatty acid composition of erythrocyte membranes was observed to be improved in infants consuming infant formula containing large lipid microspheres coated with phospholipids and with increased levels of palmitic acid at the sn-2 position of triglycerides. Detailed Implementation

[0011] Therefore, the present invention relates to a method for improving the cell membrane fatty acid composition of a human subject by administering a nutritional composition comprising lipids in the form of lipid globules, wherein... a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0012] The method of the present invention can also be described as a non-medical method for improving the fatty acid composition of cell membranes in human subjects.

[0013] For some jurisdictions, the present invention may also be described as the use of lipids in the preparation of nutritional compositions for improving the fatty acid composition of cell membranes in human subjects, wherein the lipids are in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0014] For some jurisdictions, the present invention may also be described as a nutritional composition comprising lipids in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids, and the nutritional composition is used to improve the fatty acid composition of cell membranes in human subjects.

[0015] In one aspect, the present invention relates to a method for improving the following aspects of a human subject by administering a nutritional composition comprising lipids in the form of lipid globules: i) improving cognitive performance and / or improving cognitive development and / or preventing cognitive impairment; ii) improving behavioral performance and / or improving behavioral development; iii) improving visual acuity; and / or iv) improving fine motor skills, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0016] The present invention may also be expressed as a non-medical method for improving the following aspects of human subjects: i) improving cognitive performance and / or improving cognitive development and / or preventing cognitive impairment; ii) improving behavioral performance and / or improving behavioral development; iii) improving visual acuity; and / or iv) improving fine motor skills, preferably expressed as a non-medical method for improving cognitive performance and / or improving cognitive development and / or preventing cognitive impairment in human subjects.

[0017] For some jurisdictions, the present invention may also be described as the use of lipids in the preparation of nutritional compositions for improving, in human subjects, aspects of: i) improved cognitive performance and / or improved cognitive development and / or prevented cognitive impairment; ii) improved behavioral performance and / or improved behavioral development; iii) improved visual acuity; and / or iv) improved fine motor skills, wherein the lipids are in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0018] For some jurisdictions, the present invention may also be described as a nutritional composition comprising lipids in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids, and the nutritional composition is intended to improve the following aspects of human subjects: i) improve cognitive performance and / or improve cognitive development and / or prevent cognitive impairment; ii) improve behavioral performance and / or improve behavioral development; iii) improve visual acuity; and / or iv) improve fine motor skills.

[0019] In a preferred embodiment, the method, use, or nutritional composition used for the stated purpose is for improving cognitive performance and / or improving cognitive development.

[0020] In one aspect, the present invention relates to a method for preventing and / or treating a condition in a human subject related to impaired meningeal fatty acid composition by administering a nutritional composition comprising lipids in the form of lipid globules, said condition being selected from attention deficit hyperactivity disorder (ADHD), autism, dyslexia, depression, bipolar disorder, anxiety disorder, schizophrenia, obsessive-compulsive disorder, hyperphagia, alcohol or drug abuse, borderline personality disorder, panic disorder, social phobia, cognitive impairment, dementia, Alzheimer's disease, and Parkinson's disease, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0021] For some jurisdictions, the present invention may also be described as the use of lipids in the preparation of nutritional compositions for the prevention and / or treatment of conditions in human subjects related to impaired meningeal fatty acid composition, said conditions being selected from attention deficit hyperactivity disorder (ADHD), autism, dyslexia, depression, bipolar disorder, anxiety disorder, schizophrenia, obsessive-compulsive disorder, hyperphagia, alcohol or drug abuse, borderline personality disorder, panic disorder, social phobia, cognitive impairment, dementia, Alzheimer's disease, and Parkinson's disease, wherein said lipids are in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0022] For some jurisdictions, the present invention may also be described as a nutritional composition comprising lipids in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids, and the nutritional composition is used to prevent and / or treat a condition in a human subject associated with impaired meningeal fatty acid composition, the condition being selected from attention deficit hyperactivity disorder (ADHD), autism, dyslexia, depression, bipolar disorder, anxiety disorder, schizophrenia, obsessive-compulsive disorder, hyperphagia, alcohol or drug abuse, borderline personality disorder, panic disorder, social phobia, cognitive impairment, dementia, Alzheimer's disease, and Parkinson's disease.

[0023] In a preferred embodiment, the condition associated with the damaged fatty acid composition of the meninges is a prevention of cognitive impairment.

[0024] lipids The nutritional composition provided according to the method or use of the present invention comprises lipids. Preferably, the lipids in the present invention comprise one or more of the following: triglycerides, polar lipids (e.g., phospholipids, cholesterol, glycolipids, and sphingomyelins), free fatty acids, monoglycerides, and diglycerides.

[0025] Lipids provide 30 to 60% of the total calories of the composition. More preferably, the compositions of the present invention contain lipids providing 35 to 55% of the total calories, and even more preferably, the compositions of the present invention provide 40 to 50% of the total calories. When in liquid form, for example as an instant liquid, the composition preferably contains 2.1-6.5 g lipids / 100 ml, more preferably 3.0-4.0 g / 100 ml. On a dry weight basis, the compositions of the present invention preferably contain 10 to 50% by weight, more preferably 12.5 to 40% by weight, and even more preferably 19 to 30% by weight of lipids.

[0026] The lipids of this invention comprise plant lipids. The presence of plant lipids advantageously achieves an optimal fatty acid profile, a high content of polyunsaturated fatty acids, and / or is closer to human milk fat. Using lipids solely from cow's milk or other livestock does not provide an optimal fatty acid profile. The content of essential fatty acids is too low. Such a less than ideal fatty acid profile (e.g., high levels of saturated fatty acids) is known to lead to increased obesity. Preferably, the compositions of this invention comprise at least one, preferably at least two, lipid sources selected from: linseed oil, rapeseed oil (e.g., colza oil, low erucic acid rapeseed oil, and canola oil), sunflower oil, high oleic sunflower oil, safflower oil, high oleic safflower oil, olive oil, coconut oil, palm oil, and palm kernel oil. When the composition is in liquid form, such as an instant liquid, it preferably contains 1.0-6.5 g, more preferably 1.5-4.0 g of plant lipids per 100 ml. Based on dry weight, the compositions of the present invention preferably contain 5 to 50% by weight, more preferably 6 to 40% by weight, and even more preferably 10 to 30% by weight of plant lipids. Preferably, the compositions contain 5 to 100% by weight, more preferably 5 to 95% by weight, more preferably 20 to 80% by weight, even more preferably 25 to 75% by weight, and most preferably 40 to 60% by weight of plant lipids based on total lipids. It should be noted that the compositions of the present invention may also contain non-plant lipids. Non-plant lipids may include milk fat, lipids derived from milk as a preferred source of phospholipids, and fish oil, marine oil, and / or microbial oil as a source of LC-PUFA.

[0027] Palmitic acid (PA) at the sn-2 position of triglycerides In the nutritional composition, triglycerides are the major fraction of lipids. Triglycerides comprise a glycerol moiety consisting of three fatty acid residues linked via ester bonds. These fatty acid residues may be the same or different and are generally selected from saturated and unsaturated fatty acids containing 4 to 26 carbon atoms. The fatty acid residues present in the triglycerides may be different and / or their respective positions relative to the glycerol backbone may differ (e.g., at sn-1, sn-2, and / or sn-3 positions). Preferably, the composition contains at least 70% by weight, more preferably at least 80% by weight, more preferably at least 85% by weight, even more preferably at least 90% by weight based on total lipids, and even more preferably at least 95% by weight based on total lipids.

[0028] Improved cell membrane fatty acid composition was observed when the lipid component had an increase in palmitic acid (PA) at the sn-2 position in triglycerides, based on the total PA content. Lipids that can be used to increase the total PA content at the sn-2 position in triglycerides are commercially available lipids—for example, those marketed under the name Betapol. TM The lipids were purchased from Loders Croklaan and / or could be prepared in a manner known per se (e.g., as described in EP 0698078 and / or EP 0758846). Another suitable source is InFat from Enzymotec. TM In cases where these lipids are obtained through transesterification or cross-esterification of plant triglycerides, these lipid sources are considered plant lipids in this invention.

[0029] To enhance the PA at the sn-2 or β position in triglycerides, the preferred source of triglycerides is non-human animal fat, more preferably non-human mammalian milk fat, and even more preferably bovine milk fat. Preferably, the non-human mammalian milk fat (especially bovine milk fat) is used in the form of anhydrous milk fat or butter. Preferably, the milk fat is sourced from a homogenized fat phase, such as butter or anhydrous milk fat, rather than in the form of an oil-in-water emulsion (e.g., cream), because during the preparation of the nutritional compositions of the present invention, it is easier to prepare the lipid microspheres of the present invention when the lipids are added to the aqueous phase as a homogenized fat phase (thereby homogenizing the mixture into an emulsion).

[0030] Preferably, the lipid source comprising triglycerides having an increased amount of palmitic acid residues at the sn-2 position of the triglyceride is, based on total lipids, 10 to 99.5% by weight, more preferably 10 to 80% by weight; more preferably 20 to 80% by weight, more preferably 20 to 50% by weight, even more preferably 25 to 50% by weight; such triglycerides are contained in the lipids of the nutritional composition to be given according to the method or use of the invention. This lipid source is preferably milk fat, more preferably butter or anhydrous milk fat. Preferably, the nutritional composition comprises 5 to 95% by weight, more preferably 20 to 80% by weight, based on total lipids; more preferably 25 to 75% by weight, even more preferably 40 to 60% by weight, based on total lipids.

[0031] The lipids used according to the invention are selected such that the content of palmitic acid (PA) in the total lipids of the nutritional composition, based on the total fatty acids in the total lipids, is at least 10% by weight, preferably at least 15% by weight. Preferably, the content of PA in the lipids, based on the total fatty acids in the total lipids, is less than 30% by weight, more preferably 16 to 24% by weight.

[0032] The lipids used according to the invention are selected such that, based on the total PA present in the lipids, at least 15% by weight, preferably at least 20% by weight, more preferably at least 25% by weight, and even more preferably at least 30% by weight of PA are located at the sn-2 or β position in the triglycerides. Preferably, the amount of PA at the sn-2 position in the triglycerides is at most 45% by weight, preferably at most 40% by weight, based on the total PA.

[0033] Fatty acid composition In this article, LA refers to linoleic acid chain and / or linoleoyl chain (18:2, n6); ALA refers to... -linolenic acid chains and / or - Linolenic acid chain (18:3, n3); SFA refers to saturated fatty acids and / or saturated fatty acyl chains; MUFA refers to monounsaturated fatty acids and / or monounsaturated fatty acyl chains; PUFA refers to polyunsaturated fatty acids and / or polyunsaturated fatty acyl chains with two or more unsaturated bonds; LC-PUFA refers to long-chain polyunsaturated fatty acid chains and / or long-chain polyunsaturated fatty acyl chains containing at least 20 carbon atoms and having two or more unsaturated bonds; DHA refers to docosahexaenoic acid chain and / or docosahexaenoic acid chain (22:6, n3); EPA refers to eicosapentaenoic acid chain and / or eicosapentaenoic acid chain (20:5, n3); ARA refers to arachidonic acid chain and / or arachidonic acid chain (20:4, n6); DPA refers to docosapentaenoic acid chain and / or docosapentaenoic acid chain (22:5, n3). PA refers to palmitic acid and / or palmitoyl chains (C16:0). Medium-chain fatty acids (MCFAs) refer to fatty acid chains and / or fatty acyl chains with chain lengths of 6, 8, and 10 carbon atoms. n3 or ω3 PUFAs refer to polyunsaturated fatty acids and / or polyunsaturated fatty acyl chains having two or more unsaturated bonds and an unsaturated bond on the third carbon atom from the methyl terminus of the fatty acyl chain. n6 or ω6 PUFAs refer to polyunsaturated fatty acids and / or polyunsaturated fatty acyl chains having two or more unsaturated bonds and an unsaturated bond on the sixth carbon atom from the methyl terminus of the fatty acyl chain.

[0034] The nutritional composition of the present invention preferably contains LA. LA is a precursor to n6 PUFA and n6 LC-PUFA, and is an essential fatty acid because it cannot be synthesized by the human body. LA is preferably present in an amount sufficient to promote healthy growth and development, but in the lowest possible amount to prevent negative, competitive effects on the formation of n3 PUFA and an excessively high n6 / n3 ratio. Therefore, the nutritional composition preferably contains less than 25% by weight, more preferably less than 20% by weight, and even more preferably less than 15% by weight of LA based on total fatty acids. Preferably, the nutritional composition contains at least 5% by weight, preferably at least 7.5% by weight, and even more preferably at least 10% by weight of LA based on total fatty acids.

[0035] The nutritional composition of the present invention preferably contains ALA. ALA is a precursor to n3 PUFA and n3 LC-PUFA, and is an essential fatty acid because it cannot be synthesized by the human body. ALA is preferably present in an amount sufficient to promote healthy growth and development in infants. Therefore, the nutritional composition of the present invention preferably contains at least 0.5% by weight, more preferably at least 1.0% by weight, of ALA based on total fatty acids, and more preferably at least 1.5% by weight, more preferably at least 2.0% by weight, of ALA. Preferably, the nutritional composition contains less than 10% by weight, more preferably less than 5.0% by weight, of ALA based on total fatty acids. The LA / ALA weight ratio should be very balanced to ensure optimal n6 / n3 PUFA, n6 / n3 LC PUFA, and DHA / ARA ratios in the cell membrane. Therefore, the LA / ALA weight ratio contained in the nutritional composition of the present invention is 3 to 20, more preferably 5 to 15, more preferably 5 to 12, and more preferably 5 to 10. Preferably, the weight ratio of n6 PUFA to n3 PUFA is 3 to 20, more preferably 3 to 15, more preferably 5 to 12, and even more preferably 5 to 10.

[0036] Preferably, the nutritional composition of the present invention comprises n3 LC-PUFA, such as EPA, DPA, and / or DHA, more preferably DHA. DHA is an important component of the meninges and is required for optimal function of nerve tissue. Since the conversion efficiency of ALA to DHA may be low in infants, it is preferred that both ALA and DHA are present in the nutritional composition. Preferably, the nutritional composition of the present invention comprises at least 0.05% by weight, preferably at least 0.1% by weight, and more preferably at least 0.2% by weight of DHA based on total fatty acids. Preferably, the nutritional composition of the present invention comprises up to 2.0% by weight, preferably up to 1.0% by weight of DHA based on total fatty acids.

[0037] Since ARA is important for optimally functional membranes (especially those of neural tissue) in infants, the nutritional compositions of the present invention preferably contain ARA. Preferably, the nutritional compositions of the present invention contain at least 0.05% by weight, preferably at least 0.1% by weight, and more preferably at least 0.2% by weight of ARA based on total fatty acids. Since the n6 fatty acid group (especially arachidonic acid (ARA)) counteracts the n3 fatty acid group (especially DHA), the nutritional compositions of the present invention contain a relatively small amount of ARA. Preferably, the nutritional compositions of the present invention contain at most 2.0% by weight, preferably at most 1.0% by weight of ARA based on total fatty acids. Preferably, the weight ratio of DHA to ARA is 1 / 4 to 4 / 1, more preferably 1 / 2 to 2 / 1, and more preferably 0.67 to 1.5.

[0038] The optimal fatty acid composition of the nutritional composition contributes to the optimal fatty acid composition of the cell membrane, and the increased amounts of sn-2 palmitic acid, phospholipids, and the presence of lipids in the form of large lipid globules also synergistically support the optimal fatty acid composition of the cell membrane.

[0039] size of lipid globules According to the present invention, lipids are present in the nutritional composition in the form of lipid spheres. When the nutritional composition is in liquid form, these lipid spheres are emulsified in an aqueous phase. Alternatively, the lipid spheres are present in powder form, and these powders are suitable for resolvation with water or another food-grade aqueous phase. The lipid spheres comprise a core and a surface.

[0040] Standard infant formula or growing milk contains lipid globules with a mode diameter of less than 0.5 μm. The presence of larger lipid globules has been found to improve the fatty acid composition of cell membranes.

[0041] The percentage of lipid globules is based on the volume of total lipids. The mode diameter refers to the diameter most commonly found based on the volume of total lipids, or the peak value in a graph where X represents the diameter and Y represents the volume (%).

[0042] The volume and size distribution of lipid globules can be appropriately determined using a particle size analyzer such as Mastersizer (Malvern Instruments, Malvern, UK) by methods described, for example, in Michalski et al., 2001, Lait 81: 787-796.

[0043] The core preferably contains at least 90% by weight of triglycerides, and more preferably consists essentially of triglycerides.

[0044] The volume-weighted mode diameter of the lipid globules in the nutritional composition according to the invention is 1.0 µm or more, preferably 3.0 µm or more, more preferably 4.0 µm or more, preferably 1.0 to 10 µm, more preferably 2.0 to 8.0 µm, even more preferably 3.0 to 7.0 µm, and most preferably 4.0 µm to 6.0 µm. Alternatively, or preferably additionally, the size distribution is such that at least 45% by volume, preferably at least 55% by volume, even more preferably at least 65% by volume, even more preferably at least 75% by volume, of the lipid globules has a diameter of 2 to 12 µm. More preferably, at least 45% by volume, preferably at least 55% by volume, even more preferably at least 65% by volume, even more preferably at least 75% by volume, of the lipid globules has a diameter of 2 to 10 µm. Even more preferably, at least 45% by volume, preferably at least 55% by volume, even more preferably at least 65% by volume, even more preferably at least 75% by volume, of the lipid globules has a diameter of 4 to 10 µm. Preferably, less than 5% by volume of the lipid microspheres have a diameter of 12 µm or more.

[0045] Phospholipids According to the present invention, the nutritional composition comprises polar lipids, particularly phospholipids. Polar lipids are amphiphilic and include glycerophospholipids, sphingomyelins, glycosphingolipids, and / or cholesterol. More preferably, the nutritional composition of the present invention comprises phospholipids, defined as the sum of glycerophospholipids and sphingomyelins. Phospholipids are preferably present in a coating on the surface of lipid globules. "Coating" refers to the outer surface layer of lipid globules containing phospholipids, which are hardly present in the core of the lipid globules. Phospholipids present in the diet given early in life have been found to advantageously improve the fatty acid composition of cell membranes. Preferably, a portion of the phospholipids (preferably greater than 50% by weight, more preferably greater than 70% by weight, and even more preferably greater than 85% by weight) is present in the coating. A suitable method for determining whether phospholipids are located on the surface of lipid globules is confocal laser scanning microscopy or transmission electron microscopy (see, for example, Gallier et al., 2015, Colloids Surf B Biointerfaces 136:329-339).

[0046] The nutritional compositions of the present invention preferably contain glycerophospholipids. Examples of glycerophospholipids are phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylglycerol (PG). Preferably, the nutritional compositions of the present invention contain PC, PS, PI, and / or PE, more preferably at least PC. The nutritional compositions of the present invention preferably contain sphingomyelin. Sphingomyelin has phosphocholine molecules or phosphoethanolamine molecules esterified with the 1-hydroxyl group of a ceramide. They are classified as phospholipids and sphingolipids, but not as glycerophospholipids or glycosphingolipids. Preferably, the nutritional compositions of the present invention contain 0.05 to 10% by weight, more preferably 0.1 to 5% by weight, and even more preferably 0.2 to 2% by weight of sphingomyelin based on total lipids. Preferably, the nutritional compositions of the present invention contain at least 5% by weight, more preferably 5 to 40% by weight, more preferably 10 to 35% by weight, and even more preferably 15 to 35% by weight of sphingomyelin based on total phospholipids.

[0047] The nutritional compositions of the present invention preferably also contain glycosphingolipids. The term glycosphingolipid as used herein specifically refers to glycolipids containing the amino alcohol sphingosine. The sphingosine backbone is O-linked to a charged headgroup (such as an ethanolamine, serine, or choline backbone). The backbone is also linked to a fatty acyl group via an amide. Glycosphingolipids are ceramides with one or more sugar residues linked at the 1-hydroxy site via a β-glycosidic bond. Preferably, the compositions of the present invention contain gangliosides, more preferably at least one ganglioside selected from GM3 and GD3.

[0048] Preferably, the phospholipids are derived from milk fat, more preferably from milk fat globule membrane (MFGM). Preferably, the phospholipids are derived from bovine milk lipids, more preferably from bovine MFGM. Preferably, the nutritional composition of the present invention comprises phospholipids and glycosphingolipids, and in a preferred embodiment, the weight ratio of phospholipids to glycosphingolipids is 2:1 to 10:1, more preferably 2:1 to 5:1.

[0049] Preferably, the nutritional composition of the present invention comprises 0.5 to 20% by weight of phospholipids based on total lipids, more preferably 0.5 to 10% by weight, more preferably 0.75 to 8% by weight, even more preferably 1.0 to 8% by weight, even more preferably 1.5 to 5% by weight. Preferably, the nutritional composition of the present invention comprises 0.1 to 10% by weight of glycosphingolipids based on total lipids, more preferably 0.5 to 5% by weight, even more preferably 2 to 4% by weight.

[0050] The nutritional composition of the present invention preferably contains cholesterol. The nutritional composition of the present invention preferably contains at least 0.005% by weight, more preferably at least 0.02% by weight, more preferably at least 0.05% by weight, and even more preferably at least 0.1% by weight of cholesterol based on total lipids. Preferably, the amount of cholesterol based on total lipids is no more than 10% by weight, more preferably no more than 5% by weight, and even more preferably no more than 1% by weight of total lipids.

[0051] Preferred sources for providing phospholipids, glycosphingolipids, and / or cholesterol are lecithin, milk fat, buttermilk fat, and cream whey fat (such as β-whey fat). Preferred sources of phospholipids (especially PC) are soybean lecithin and / or sunflower lecithin. The nutritional composition of the present invention preferably contains phospholipids derived from mammalian milk. The nutritional composition of the present invention preferably contains milk-derived phospholipids and glycosphingolipids. Cholesterol is also preferably obtained from milk. Milk-derived phospholipids include phospholipids isolated from milk lipids, cheese lipids, cheese whey lipids, cream whey lipids (β-whey lipids), whey lipids, cheese lipids, and / or buttermilk lipids. Buttermilk lipids are typically obtained during the preparation of buttermilk. Cream whey lipids or β-whey lipids are typically obtained during the preparation of anhydrous milk fat from cream. Preferably, phospholipids, glycosphingolipids, and / or cholesterol are obtained from dairy cream. The nutritional composition preferably contains phospholipids, glycosphingolipids, and / or cholesterol from the milk of cows, donkeys, sheep, goats, buffalo, horses, and camels. The preferred method is to use lipid extracts isolated from cow's milk. The use of phospholipids from milk fat advantageously incorporates the milk fat globule membrane, which is more similar to that found in human milk. Therefore, the combined use of polar lipids (particularly phospholipids) from domesticated animal milk and triglycerides from plant lipids allows for the preparation of coated lipid globules with a coating more similar to that of human milk, while providing an optimal fatty acid profile. Suitable commercially available sources of milk polar lipids are BAEF, SM2, SM3, and SM4 powders from Corman, Salibra of Glanbia, and LacProdan MFGM-10 or PL20 from Arla.

[0052] Methods for obtaining lipid microspheres with increased size and / or phospholipid coating are, for example, those disclosed in WO2010 / 0027258 and WO2010 / 0027259.

[0053] The presence of large lipid globules and increased phospholipids improved the fatty acid composition of the membrane and enhanced cognitive performance. Furthermore, the optimal dietary fatty acid composition and the presence of increased palmitic acid at the sn-2 position also contributed to a synergistic effect on membrane composition.

[0054] Nutritional composition Digestible carbohydrates The nutritional composition preferably contains digestible carbohydrates. The digestible carbohydrates preferably provide 30 to 80% of the total calories of the composition. Preferably, the digestible carbohydrates provide 40 to 60% of the total calories. When in liquid form, for example as an instant liquid, the composition preferably contains 3.0-30 g of digestible carbohydrates per 100 ml, more preferably 6.0-20 g, and even more preferably 7.0-10.0 g per 100 ml. Based on dry weight, the composition of the present invention preferably contains 20 to 80% by weight, more preferably 40 to 65% by weight of digestible carbohydrates.

[0055] Preferred sources of digestible carbohydrates include lactose, glucose, sucrose, fructose, galactose, maltose, starch, and maltodextrin. Lactose is the main digestible carbohydrate found in human milk. Lactose advantageously has a low glycemic index. The nutritional compositions of the present invention preferably contain lactose. The nutritional compositions of the present invention preferably contain digestible carbohydrates, wherein at least 35% by weight, more preferably at least 50% by weight, more preferably at least 75% by weight, even more preferably at least 90% by weight, and most preferably at least 95% by weight of the digestible carbohydrates are lactose. Based on dry weight, the compositions of the present invention preferably contain at least 25% by weight, preferably at least 40% by weight of lactose.

[0056] Indigestible carbohydrates In one embodiment, the nutritional composition of the present invention comprises indigestible oligosaccharides. Preferably, the nutritional composition of the present invention comprises indigestible oligosaccharides with a degree of polymerization (DP) of 2 to 250, more preferably 3 to 60. These indigestible oligosaccharides improve the gut microbiota and have a beneficial effect on the brain across the gut-brain barrier.

[0057] Preferably, the nutritional composition of the present invention comprises fructooligosaccharides, galactooligosaccharides, and / or galacturonic acid oligosaccharides, more preferably galactooligosaccharides, and most preferably trans-galactooligosaccharides. In a preferred embodiment, the composition comprises a mixture of trans-galactooligosaccharides and fructooligosaccharides. Suitable indigestible oligosaccharides are, for example, Vivinal® GOS (FrieslandCampina DOMO), Raftilin® HP, or Raftilose® (Orafti).

[0058] Preferably, the nutritional composition comprises 80 mg to 2 g / 100 ml, more preferably 150 mg to 1.50 g / 100 ml, and even more preferably 300 mg to 1 g / 100 ml of indigestible oligosaccharides. Based on dry weight, the nutritional composition preferably comprises 0.25% to 20% by weight, more preferably 0.5% to 10% by weight, and even more preferably 1.5% to 7.5% by weight of indigestible oligosaccharides. Lower amounts of indigestible oligosaccharides will be less effective in improving the microbiota, while excessive amounts can lead to side effects such as bloating and abdominal discomfort.

[0059] protein The nutritional composition of the present invention preferably comprises protein. The protein preferably provides 5 to 15% of the total calories. Preferably, the nutritional composition of the present invention comprises protein providing 6 to 12% of the total calories. More preferably, the protein present in the nutritional composition is less than 2.25 g / 100 kcal, even more preferably the nutritional composition comprises 1.8 to 2.1 g protein / 100 kcal, and even more preferably 1.85 to 2.0 g protein / 100 kcal. Advantageously, a lower protein concentration is closer to that of human milk, because human milk contains less protein than cow's milk based on total calories. The protein concentration in the nutritional composition is determined by the sum of protein, peptides, and free amino acids. Based on dry weight, the nutritional composition preferably comprises less than 12% by weight, more preferably 9.6 to 12% by weight, and even more preferably 10 to 11% by weight of protein. Based on ready-to-drink liquid products, the nutritional composition preferably comprises less than 1.5 g per 100 ml, more preferably 1.2 to 1.5 g, and even more preferably 1.25 to 1.35 g of protein.

[0060] The protein source should be selected to meet the minimum requirements for essential amino acid content and ensure satisfactory growth. Therefore, protein sources based on the following are preferred: bovine milk proteins, such as whey, casein, and mixtures thereof, and proteins based on soybeans, potatoes, or peas. When using whey protein, the protein source is preferably based on acidic or sweet whey, whey protein isolates, or mixtures thereof. Preferably, the nutritional composition comprises at least 3% by weight of casein based on dry weight. Preferably, the casein is intact and / or unhydrolyzed. For the purposes of this invention, the protein comprises peptides and free amino acids.

[0061] Other ingredients The nutritional composition of the present invention is preferably particularly suitable for providing daily nutritional needs for individuals under 36 months of age, especially infants under 24 months of age, even more preferably infants under 18 months of age, and most preferably infants under 12 months of age. Therefore, the nutritional composition is intended for feeding or for use in feeding human subjects. The nutritional composition of the present invention preferably comprises lipids, proteins, and digestible carbohydrates, wherein the lipids preferably provide 30 to 60% of the total calories, the protein component preferably provides 5 to 15% by weight of the total calories, and the digestible carbohydrates preferably provide 30 to 80% of the total calories. Preferably, the nutritional composition of the present invention comprises lipids providing 35 to 55% of the total calories, protein providing 6 to 12% of the total calories, and digestible carbohydrates providing 40 to 60% of the total calories. In one embodiment, the protein provides 5 to 9% of the total calories.

[0062] Preferably, the nutritional composition of the present invention comprises providing 10 to 50% by weight of lipids based on the dry weight of the nutritional composition, providing 9.6 to 12% by weight of protein based on the dry weight of the nutritional composition, providing 20 to 80% by weight of digestible carbohydrates based on the dry weight of the nutritional composition, and optionally 0.25 to 20% by weight of indigestible oligosaccharides based on the dry weight of the nutritional composition.

[0063] Preferably, the composition of the present invention is not human milk. The nutritional composition of the present invention is not (unprocessed) cow's milk or other (unprocessed) mammalian milk. The nutritional composition of the present invention preferably contains plant lipids. The nutritional composition of the present invention preferably contains other ingredients according to international guidelines for infant formula, such as vitamins, minerals, trace elements, and other micronutrients.

[0064] In one embodiment, the nutritional composition according to the invention, or the nutritional composition used according to the invention, is an infant formula, a follow-up formula, or a growing milk.

[0065] To meet the infant's caloric needs, the nutritional composition preferably contains 50 to 200 kcal / 100 ml of liquid, more preferably 60 to 90 kcal / 100 ml of liquid, and even more preferably 60 to 75 kcal / 100 ml of liquid. This caloric density ensures an optimal ratio between water and caloric expenditure. The molar osmotic pressure of the nutritional composition of the present invention is preferably 150 to 420 mOsmol / L, more preferably 260 to 320 mOsmol / L. The low molar osmotic pressure aims to reduce gastrointestinal stress. Stress can adversely affect cognitive development.

[0066] Preferably, the nutrient composition is in liquid form, which is soluble in water at 20°C and 100 s. -1At the shear rate, the viscosity, as measured by a Brookfield viscometer, is less than 35 mPa·s, more preferably less than 6 mPa·s. In one embodiment, the composition of the present invention is a powder. Suitably, the composition is in powder form (which can be reconstituted with water or another food-grade aqueous phase to form a ready-to-drink liquid) or in liquid concentrate form (which should be diluted with water to a ready-to-drink liquid). It has been found that the lipid globules retain their size and coating after reconstitution.

[0067] application The nutritional composition of the present invention is administered to human subjects, preferably orally.

[0068] The inventors unexpectedly discovered that feeding mice early in life with a diet composition containing large phospholipid-rich lipid globules and palmitic acid enriched at the sn-2 position of triglycerides resulted in a synergistic effect on meningeal composition later in life compared to feeding mice in infancy and childhood with a diet composition having a similar fatty acid composition but lacking large phospholipid-rich lipid globules and / or not enriched at the sn-2 position of triglycerides. This synergistic effect, exceeding the effect expected based on a single factor, was observed compared to feeding only sn-2 palmitic acid or large phospholipid-rich lipid globules. The meningeal fatty acid composition was significantly different and impaired in control mice fed standard infant formula early in life followed by exposure to a Western diet compared to control mice fed rodent food but not exposed to a Western diet. This condition could be partially prevented by diets containing only lipids rich in palmitic acid at the sn-2 position or only large phospholipid-rich lipid globules, but the best and most significant effect was observed when both were used simultaneously.

[0069] The effects were observed, in particular, when the concentrations of one or more of the following were increased: meningeal PUFA, n3 and n6 PUFA, LC-PUFA, n3 and n6 LC-PUFA, DHA, and ARA.

[0070] In clinical trials, the nutritional compositions of the present invention were administered to infants up to 17 weeks of age. Analysis of the red blood cell (RBC) membrane composition revealed that the RBC membrane composition was more similar to that of breastfed infants compared to infants consuming standard formula. In one embodiment of the invention, the cell membrane is the red blood cell membrane. Specifically, the amount of PUFA is increased and the n6 / n3 PUFA ratio is decreased. In one embodiment of the invention, improving the fatty acid composition of the red blood cell membrane is selected from one or more of increasing PUFA and decreasing the n6 / n3 LC-PUFA weight ratio. In one embodiment of the invention, improving the cell membrane is selected from increasing membrane fluidity, increasing PUFA, increasing LC-PUFA, increasing n3 PUFA, increasing n3 LC-PUFA, increasing DHA, increasing ARA, decreasing the n6 / n3 PUFA weight ratio, and decreasing the n6 / n3 LC-PUFA weight ratio. Preferably, improving cell membranes is selected from increasing membrane fluidity, increasing PUFA, increasing LC-PUFA, increasing n3 PUFA, increasing n3LC-PUFA, increasing DHA, and increasing ARA. In one embodiment of the invention, the improvement of cell membranes is in brain cell membranes, and in one embodiment, the improvement of brain cell membranes is selected from increasing membrane fluidity, increasing LC-PUFA, increasing n3 LC-PUFA, and increasing DHA, more preferably from increasing LC-PUFA and increasing DHA. In one embodiment of the invention, the improvement of cell membranes is in erythrocyte membranes, and in one embodiment, the improvement of erythrocyte membranes is selected from increasing membrane fluidity, increasing LC-PUFA, increasing n3 LC-PUFA, increasing DHA, reducing the weight ratio of n6 / n3 PUFA, and reducing the weight ratio of n6 / n3 LC PUFA, more preferably from increasing LC-PUFA, increasing DHA, reducing the weight ratio of n6 / n3 PUFA, and reducing the weight ratio of n6 / n3 LC PUFA.

[0071] In terms of structure and function, brain growth and development are at their peak during the second trimester and the first three years of life, and continue into adolescence and adulthood.

[0072] During early development, brain growth and functional development are highly sensitive to environmental signals, including an adequate supply of nutrients. The brain's dry weight is composed of approximately 60% fat, and dietary fat directly influences the structure and composition of brain cell membranes. The transmission of electrical signals between neurons and the continuous rebuilding of connections between neurons make the brain the most energy-intensive organ in the body, thus requiring a structure different from other parts of the body. Synapses, the most important component in neuronal transmission, are composed of DHA-rich phospholipids. DHA plays a building block role in cell membranes, synapse formation, and neurotransmitter production (signals used for transmission). In the first few months of life, the total amount of DHA in the brain increases dramatically, not only due to the increase in organ size and cell number but also due to the increased incorporation of DHA into cell membranes. The rate of DHA incorporation into the brain remains significant until at least 2 years of age. Because it is beneficial for developing children, the beneficial effects of incorporating n3 and n6 (LC-)PUFAs, especially DHA, into cell membranes in early life are advantageous. Therefore, it is preferable to administer the nutritional composition of the present invention to human subjects during the first 3 years of life. In one embodiment of the invention, the nutritional composition is given or fed to or used to feed human subjects aged 0 to 36 months. Advantageously, the composition of the invention is given to humans aged 0-24 months, more preferably to humans aged 0-18 months, even more preferably to humans aged 0-12 months, and most preferably to humans aged 0-6 months.

[0073] Functional brain effects Similar to human breast milk, the nutritional compositions of this invention provide essential brain building blocks, such as DHA and phospholipids, that are relevant to early life brain development. These building blocks are now part of a lipid globule structure more closely resembling that of human breast milk and, without being bound by theory, support more efficient transport and incorporation into cell membranes compared to standard infant formula. In one embodiment of the invention, the cell membrane is the brain cell membrane.

[0074] Studies in WO2011 / 115476 and WO2011 / 115491 have shown that the fatty acid composition of the meninges is directly related to functional brain effects later in life. A low ratio of n6 / n3 PUFAs has beneficial effects on brain function. McCann et al., 2005, Am J Clin Nutr, 82:281-295, reviewed clinical and animal studies on the effects of meningeal composition on brain function and concluded that changes in brain DHA concentration are positively correlated with changes in cognitive or behavioral performance. Similarly, impaired meningeal fatty acid composition, such as lower levels of (LC-)PUFAs, higher n6 / n3 ratios of (LC-)PUFAs, and / or lower levels of n3 (LC-)PUFAs (especially DHA), is associated with brain disorders such as attention deficit hyperactivity disorder (ADHD), autism, dyslexia, depression, bipolar disorder, anxiety disorders, schizophrenia, obsessive-compulsive disorder, hyperphagia, alcohol or drug abuse, borderline personality disorder, panic disorder, social phobia, cognitive impairment, dementia, Alzheimer's disease, and Parkinson's disease.

[0075] In one aspect, the present invention relates to a method for improving the following aspects by improving the fatty acid composition of the brain cell membranes of human subjects: i) improving cognitive performance and / or improving cognitive development and / or preventing cognitive impairment, ii) improving behavioral performance and / or improving behavioral development, iii) improving visual acuity, and / or iv) improving fine motor skills; preferably, a method for improving cognitive performance, improving cognitive development, and / or preventing cognitive impairment by improving the fatty acid composition of the brain cell membranes of human subjects; said method is carried out by administering a nutritional composition to the human subject comprising lipids in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0076] The present invention can also be expressed as a non-medical method for improving the following aspects by improving the fatty acid composition of the brain cell membranes of human subjects: i) improving cognitive performance and / or improving cognitive development and / or preventing cognitive impairment, ii) improving behavioral performance and / or improving behavioral development, iii) improving visual acuity, and / or iv) improving fine motor skills; preferably expressed as a non-medical method for improving cognitive performance, improving cognitive development and / or preventing cognitive impairment by improving the fatty acid composition of the brain cell membranes of human subjects.

[0077] For some jurisdictions, the present invention may also be described as the use of lipids in the preparation of nutritional compositions that, by improving the fatty acid composition of brain cell membranes in human subjects, are used for: i) improving cognitive performance and / or improving cognitive development and / or preventing cognitive impairment; ii) improving behavioral performance and / or improving behavioral development; iii) improving visual acuity; and / or iv) improving fine motor skills; preferably by improving the fatty acid composition of brain cell membranes in human subjects for improving cognitive performance, improving cognitive development, and / or preventing cognitive impairment; wherein the lipids are in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2-12 μm, and d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0078] For some jurisdictions, the present invention may also be described as a nutritional composition comprising lipids in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids, and the nutritional composition is used to improve the fatty acid composition of the brain cell membranes of human subjects for the following purposes: i) improving cognitive performance and / or improving cognitive development and / or preventing cognitive impairment, ii) improving behavioral performance and / or improving behavioral development, iii) improving visual acuity, and / or iv) improving fine motor skills; preferably for improving cognitive performance, improving cognitive development and / or preventing cognitive impairment by improving the fatty acid composition of the brain cell membranes of human subjects.

[0079] In one aspect, the present invention relates to a method for preventing and / or treating conditions related to impaired meningeal fatty acid composition by improving the fatty acid composition of brain cell membranes in human subjects, said conditions being selected from attention deficit hyperactivity disorder (ADHD), autism, dyslexia, depression, bipolar disorder, anxiety disorder, schizophrenia, obsessive-compulsive disorder, hyperphagia, alcohol or drug abuse, borderline personality disorder, panic disorder, social phobia, cognitive impairment, dementia, Alzheimer's disease, and Parkinson's disease, the method being carried out by administering a nutritional composition to a human subject comprising lipids in the form of lipid globules, wherein... a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0080] For some jurisdictions, the present invention may also be described as the use of lipids in the preparation of nutritional compositions that prevent and / or treat conditions related to impaired meningeal fatty acid composition by improving the fatty acid composition of brain cell membranes in human subjects, said conditions being selected from attention deficit hyperactivity disorder (ADHD), autism, dyslexia, depression, bipolar disorder, anxiety disorder, schizophrenia, obsessive-compulsive disorder, hyperphagia, alcohol or drug abuse, borderline personality disorder, panic disorder, social phobia, cognitive impairment, dementia, Alzheimer's disease, and Parkinson's disease, wherein said lipids are in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0081] For some jurisdictions, the present invention may also be described as a nutritional composition comprising lipids in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition described herein is not human milk, or the nutritional composition described herein contains plant lipids, and the nutritional composition prevents and / or treats conditions related to impaired meningeal fatty acid composition by improving the fatty acid composition of brain cell membranes in human subjects, the conditions being selected from attention deficit hyperactivity disorder (ADHD), autism, dyslexia, depression, bipolar disorder, anxiety disorder, schizophrenia, obsessive-compulsive disorder, hyperphagia, alcohol or drug abuse, borderline personality disorder, panic disorder, social phobia, cognitive impairment, dementia, Alzheimer's disease, and Parkinson's disease.

[0082] In this invention, cognitive performance or cognitive development preferably refers to any of the following: memory performance or development (e.g., short-term memory, long-term memory, episodic memory), learning ability, alertness, attention, language development, cognitive flexibility, inhibitory control, executive function, and concentration; more preferably, memory performance, attention, language development, and executive function. Therefore, in one embodiment of this invention, improving cognitive performance or cognitive development is selected from improving the following aspects: memory performance or memory development, learning ability, alertness, attention, language development, cognitive flexibility, inhibitory control, executive function, and concentration. In one embodiment of this invention, preventing cognitive impairment is selected from preventing impairment in the following aspects: memory performance or memory development, learning ability, alertness, attention, language development, cognitive flexibility, inhibitory control, executive function, and concentration.

[0083] An appropriate method for assessing the cognitive effects of improved cognitive function in young children is the NIH Toolbox Early Childhood Cognition Battery (NIH 2012, Mungas et al., 2013 Monogr Soc Res Child Dev 78:103-118). This system, recommended for children aged 3-6 years, consists of four tasks: Dimension Change Card Sort (DCCS), Flanker task, picture sequence memory, and picture vocabulary test, used to assess attention, memory, language, and executive function. DCCS is a measure of cognitive flexibility. The Flanker task measures both attention and inhibitory control. Picture sequence memory is a measure developed to assess episodic memory.

[0084] The development of younger toddlers and infants can also be assessed, for example, using the Bayley Scales of Infant and Toddler Development (Bayley-III). This includes cognitive, linguistic, and motor scales. There are also two Bayley-II scales that rely on parental reports, including the Social-Emotional Scale and the Adaptive Behavior Scale. The Bayley-III cognitive and linguistic scales are good predictors of preschool mental development performance.

[0085] Behavioral performance includes social behavior, anxiety behavior, and social interest and social cognition. Preferably, the behavioral performance is social performance and / or anxiety behavior, more preferably social performance, and even more preferably social interest and / or social cognition.

[0086] Later life Using animal models, it has been found that the beneficial effects of a diet in early life can be extended into later life after the diet has been discontinued, exhibiting long-term sustained effects. Preferably, the present invention is considered beneficial to infants aged 36 months and older. In one embodiment, when the human subject is 36 months or older, preferably 5 years or older, particularly 11 years or older, and more particularly 18 years or older, the present invention is used to achieve improvements in the fatty acid composition of cell membranes (preferably brain cell membranes) and / or to achieve improvements in cognitive performance, improvements in cognitive development and / or prevention of cognitive impairment, improvements in behavioral development, improvements in behavioral performance, improvements in visual acuity, improvements in fine motor skills, and to prevent conditions related to impaired meningeal fatty acid composition. In one embodiment, the methods or nutritional compositions of the present invention are used to feed human subjects aged 0 to 36 months, and the aforementioned improvements and preventions are achieved when the human subject is 36 months or older, preferably 5 years or older, particularly 11 years or older, and especially 18 years or older.

[0087] Preferably, improvements in the fatty acid composition of cell membranes (preferably brain cell membranes) and / or improvements in cognitive development and / or improvements in cognitive performance and / or prevention of cognitive impairment are extended after administration of the nutritional composition of the present invention. In one embodiment, later in life, preferably at least one year after discontinuation of the nutritional composition, preferably at least two years, more preferably at least three years after discontinuation of the nutritional composition, the present invention is used to achieve improvements in the fatty acid composition of cell membranes (preferably brain cell membranes) and / or to achieve improvements in cognitive development and / or improvements in cognitive performance and / or prevention of cognitive impairment and / or improvements in behavioral development and / or improvements in behavioral performance and / or improvements in visual acuity and / or improvements in fine motor skills and / or prevention of diseases related to impaired meningeal fatty acid composition.

[0088] In one implementation, the aforementioned improvements and / or prevention can also be achieved later in life when human subjects are exposed to or raised in an obesity-inducing environment and / or consume a Western diet high in fat and saturated fatty acids (fat providing more than 35% of total dietary calories and saturated fatty acids providing more than 10% of total dietary calories) after infancy. In a preferred implementation, the Western diet contains fat providing 35% to 45% of total dietary calories and saturated fatty acids providing 10% to 20% of total dietary calories.

[0089] Although the nutritional composition is particularly suitable for infants, it is also suitable for other subjects due to its long-term effects and the greater plasticity of the infant brain.

[0090] Obesity-inducing environment Preferably, the nutritional composition of the present invention is administered to human subjects, more preferably human subjects aged 0 to 36 months, and even more preferably infants exposed to or raised in an obesity-inducing environment. In the animal studies employed, animals exposed to a Western diet—representing a mild exposure to an obesity-inducing environment (e.g., current dietary styles / habits in modern Western societies)—followed by nutritional intervention in early life, were found to have an adverse effect on the composition of meningeal fatty acids. This adverse effect can be prevented by using the diet of the present invention in early life. The term obesity-inducing environment refers to an environment within the home or workplace that promotes weight gain and is detrimental to weight loss (Swinburn et al., 1999, Pev Medicine 29: 563-570). In other words, an obesity-inducing environment is an environment that promotes, induces, contributes to, or causes obesity. The contributing factor is urbanization, often accompanied by reduced physical activity and easy access to food. There is evidence that the food environment in an obesity-inducing environment not only leads to an increased incidence of obesity but also to cognitive impairment and / or the development of dementia, particularly cognitive impairment in learning and memory functions, especially those dependent on hippocampal integrity. Therefore, in one embodiment of the invention, the prevented cognitive impairment is cognitive impairment induced by a Western diet high in fat and saturated fatty acids, wherein fat in the Western diet provides more than 35% of the total dietary calories and saturated fatty acids provide more than 10% of the total dietary calories. More specifically, the prevented cognitive impairment is cognitive impairment induced by a Western diet characterized by containing fat providing 35% to 45% of the total dietary calories and saturated fatty acids providing 10% to 20% of the total dietary calories.

[0091] In one embodiment, the present invention relates to a method for preventing cognitive impairment induced in a human subject by a Western diet high in fat and saturated fatty acids by administering a nutritional composition comprising lipids in the form of lipid globules, wherein fat in the Western diet provides more than 35% of the total dietary calories and saturated fatty acids provide more than 10% of the total dietary calories, wherein... a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0092] The method of this invention can also be referred to as a non-medical method for preventing cognitive impairment induced by a Western diet.

[0093] For some jurisdictions, the present invention may also be described as the use of lipids in the preparation of nutritional compositions for the prevention of cognitive impairment in human subjects induced by a Western diet high in fat and saturated fatty acids, wherein the fat in the Western diet provides more than 35% of the total dietary calories and the saturated fatty acids provide more than 10% of the total dietary calories, wherein the lipids are in the form of lipid globules. a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

[0094] For some jurisdictions, the present invention may also be described as a nutritional composition comprising lipids in the form of lipid globules, wherein a. The lipid comprises at least 0.5% by weight of α-linolenic acid based on total fatty acids and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2 to 12 μm. d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids, and the nutritional composition is intended to prevent cognitive impairment induced in human subjects by a Western diet high in fat and saturated fatty acids, wherein fat in the Western diet provides more than 35% of the total dietary calories and saturated fatty acids provide more than 10% of the total dietary calories.

[0095] In a preferred embodiment, the Western-style diet contains fat providing 35% to 45% of the total dietary calories and saturated fatty acids providing 10% to 20% of the total dietary calories.

[0096] To better understand this, it should be noted that saturated fatty acids are a type of fat.

[0097] In this specification and its claims, the verb "comprising" and its variations are used in a non-limiting sense, meaning to include the items following the word, but not to exclude items not specifically mentioned. Furthermore, the use of the indefinite article "a" or "an" does not exclude the possibility of more than one or more of the stated elements, unless the context clearly indicates that there is only one or only one stated element. Therefore, the indefinite article "a" or "an" generally means "at least one or more".

[0098] Example Example 1: Synergistic effect of sn-2 palmitic acid and lipid microsphere design on brain fatty acid composition in later life The following experiments were conducted in which the effects of an infant formula milk containing standard plant lipids (IMF) were compared with those of the IMF of the present invention, the latter having lipid components comprising triglycerides having an increased amount of palmitic acid at their sn-2 position, and / or lipid globules with increased size and containing an increased amount of phospholipids.

[0099] The offspring of C57 / BL6 mother mice were fed only with breast milk until day 16 after birth. From day 16 onwards, the mother mice and their offspring were exposed to the experimental diet. From day 16 to day 21 after birth, the offspring were primarily fed the experimental diet, but were also allowed to drink breast milk. From day 21 onwards, the offspring were fed exclusively the experimental diet. The experimental diet was provided in dough form and the mice were continuously exposed to this diet until day 42. From day 42 to day 98, all pups were fed the same diet based on the AIN-93G diet, which contained an adjusted lipid fraction containing 20% ​​by weight of lipids (17% by weight of lard, 3% by weight of soybean oil, and 0.1% by weight of cholesterol). This represents a light Western-style (WSD) diet providing approximately 40% of total calories and containing approximately 14.5% saturated fatty acids based on total calories, thus exhibiting an increased level of fat and a percentage increase in saturated fatty acids based on total energy compared to what is considered a healthy diet.

[0100] The experimental diet used in early life consisted of 282 g of experimental infant formula milk (IMF / kg). The remaining components of the diet were AIN-93G protein, carbohydrates, and fiber. All lipids present in the diet were derived from IMF. The total lipid content was 7% by weight based on the final dry weight of the animal diet.

[0101] Experimental IMFs for diets 3 and 4 (NUT and NUT-AMF), which are present in different diets, were prepared in a manner similar to that described in Example 1B of WO2010 / 0027259. The lipid globules from these diets were relatively large. Diets 1 and 2 (CTR and AMF) were prepared using high-pressure homogenization to obtain smaller lipid globules.

[0102] Detailed characteristics of the fat composition of the different experimental IMFs used in different animal diets are shown in Table 1. In all four experimental diets, based on total fatty acids, the amounts of DHA were 0.2 wt% and ARA were 0.36 wt%. In all four diets, the amounts of linoleic acid were approximately 14 wt%, ALA was approximately 2.6 wt%, and the LA / ALA ratio was 5.4. Furthermore, the remaining fatty acid compositions of the four diets were very similar. The n6 / n3 PUFA ratio was approximately 5 in all diets, and the n6 / n3 LC PUFA ratio was approximately 1.5.

[0103] For Diet 1 (CTR), a mixture of palm oil, low-erucic acid rapeseed oil, coconut oil, high-oleic sunflower oil, sunflower oil, a small amount of soy lecithin, and LC-PUFA premix was used. In the final experimental IMF, the amount of vegetable fat was approximately 98% by weight based on total fat, and the amount of milk fat was approximately 1% by weight.

[0104] For Diet 2 (AMF), a mixture of anhydrous milk fat, coconut oil, low-erucic acid rapeseed oil, sunflower oil, high-oleic sunflower oil, a small amount of soy lecithin, and LC-PUFA premix is ​​used. The amount of vegetable fat is approximately 53% by weight based on total fat, and the amount of milk fat is approximately 47% by weight.

[0105] Dietary 3 (NUT) is similar to Dietary 1, but additionally includes buttermilk powder as a source of milk-derived phospholipids. In the final experimental IMF, the amount of plant fat was approximately 94% by weight based on total fat, and the amount of milk fat was approximately 5% by weight.

[0106] Dietary 4 (NUT-AMF) of the present invention is similar to Dietary 2, but additionally includes buttermilk powder as a source of milk-derived phospholipids as in Dietary 3. A small amount of anhydrous milk fat is added to compensate for the milk fat present in the buttermilk powder. The amount of vegetable fat is approximately 51% by weight based on total fat. The amount of milk fat is approximately 48% by weight.

[0107] Mice were weighed twice weekly. At 98 days of age, male mice were euthanized and organs including the brain were excised. One hemisphere from each brain was homogenized in 50 volumes of ice-cold deionized water (MiliQ) (Utra-Turrax T25basic, IKA, VWR International). Subsequently, the fatty acid (FA) profile of the brain was quantified by gas chromatography. 1 ml of brain homogenate was extracted according to the Bligh & Dyer method (dichloromethane / methanol extraction). Concentrated sulfuric acid in methanol converted the lipids to methyl esters. Fatty acid methyl esters (FAME) were extracted from the methanol solution with hexane and analyzed on a gas chromatograph (GC) equipped with a flame ionization detector (FID).

[0108] Table 1 Characteristics of the fat composition of the experimental diet : based on total fatty acids (by weight %) : based on total lipids (weight %) "Based on the mode diameter of the volumetric gauge, in µm."

[0109] # Percentage of lipid spheres with diameters of 2 to 12 µm, based on volumetric measurement.

[0110] result: On day 98, the FA spectrum of the brain was measured. Table 2 shows the general FA spectrum of the brain (PUFA, LCPUFA, n3, n6, n3 LC-PUFA, n6 LC-PUFA) and the spectrum of the most relevant specific LC-PUFAs (DHA and ARA).

[0111] Table 2 suggests that the brain fatty acid (FA) composition of mice fed the control formulation early in life followed by exposure to the WSD diet differed significantly from the control reference (CTR ref) group, as the CTR WSD group showed lower levels of PUFA, LC-PUFA, n3 PUFA, n3LC PUFA, DHA, n6 PUFA, n6 LC PUFA, and ARA. Compared to observations in control mice, diets containing large lipid globules and phospholipids or diets containing anhydrous milk fat improved the effects and increased levels of PUFA, LC-PUFA, n3 PUFA, n3 LC PUFA, DHA, n6 PUFA, n6 LC PUFA, and ARA. However, the greatest effects were observed in experimental diets containing both anhydrous milk fat and large lipid globules with phospholipids. These effects were statistically significant.

[0112] Table 2 The effect of early-life nutritional intervention on meningeal composition in later life after exposure to a Western diet (by weight %). Compared to CTR ref, p < 0.1. Compared with CTR REF, p < 0.05; compared with CTRL WSD, #p < 0.05.

[0113] Table 3 illustrates the synergistic effect of anhydrous milk fat (AMF) rich in palmitic acid at the sn-2 position and large lipid globules containing phospholipids. Here, the brain FA composition of the CTR WSD diet 1 group was set to zero, and the differences in fatty acid composition between the different diet groups are given. For diet 2 containing AMF and diet 3 containing large lipid globules and phospholipids (NUT), increases in all FAs shown were observed. The additive effect (Δtheoretical AMF + NUT) for the two diets was calculated in the last column. Surprisingly, however, the effect of the diet containing both AMF and large lipid globules (AMF + NUT) indicates that the increase in all FAs shown was greater than expected based on the additive effect alone.

[0114] These data indicate an improvement in the fatty acid composition of cell membranes, particularly the meninges. These results suggest improved functional brain performance or development, especially cognitive performance or development. In particular, these effects are characterized later in life, extending beyond the period during which dietary intake is provided earlier in life.

[0115] Table 3 Difference in fatty acid composition of the meninges in later life after exposure to a Western diet compared to a control diet (CTRWSD) Set the value of CTR-WSD to 0.

[0116] Example 2: The effect of IMF containing increased sn2-palmitic acid, phospholipids, and large lipid microspheres on erythrocyte (RBC) membranes. The role of fatty acid composition In a multinational, randomized, double-blind, prospective, controlled clinical trial, infants aged up to 35 days were enrolled and assigned to receive one of two formulas until 17 weeks of age: 1) control: standard infant formula milk containing the lipid components of Diet 1 as described in Example 1, or 2) experimental: infant formula containing larger phospholipid-coated lipid globules and milk fat as described in Diet 4 as described in Example 1. The formula compositions were identical except for their lipid quality (66 kcal, 1.3 g protein, 7.3 g carbohydrates, and 3.4 g fat / 100 ml). A control group of infants exclusively breastfed until at least 13 weeks of age was included. Blood samples were collected from subgroups when infants were 3 months of age. Thirty-one infants were enrolled in the experimental subgroup, 25 in the control subgroup, and 25 in the breastfed control subgroup.

[0117] result: Compared with the control group (based on total fatty acids, mean 31.57%, median 32.5%), the experimental group had the highest PUFA concentration in the RBC membrane (experiment: based on total fatty acids, mean 31.79%, median 33.7%), with the difference in median determined by the Mann-Whitney test being p = 0.05.

[0118] A trend was observed where the n3 PUFA and n3 LC-PUFA were higher in the experimental group than in the control group, and closer to those in the breastfed group. A similar trend was observed where the n6 / n3 PUFA ratio was lower in the experimental group, and closer to that in the breastfed group. The strongest influence was observed on the n6 / n3 LC-PUFA ratio: the mean was 3.00 and the median was 2.9 in the experimental group; the mean was 3.36 and the median was 3.1 in the control group; and the mean was 2.74 and the median was 2.7 in the breastfed control group. Therefore, the n6 / n3 LC-PUFA ratio in the experimental group was closer to that in the breastfed group. The difference in median values ​​between the experimental and control groups was determined by the Mann-Whitney test, with a p = 0.03.

[0119] These results indicate that, in particular, the fatty acid composition of cell membranes—especially RBC membranes—is improved when infants consume the diet of the present invention.

Claims

1. Use of lipids in the form of lipid globules for the preparation of nutritional compositions intended to improve cognitive performance and / or improve cognitive development and / or prevent cognitive impairment in human subjects, wherein... a. The lipid comprises at least 0.5% by weight of α-linolenic acid and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume, or at least 45% by volume of the lipid spheres have a diameter of 2-12 μm, and d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, wherein a portion of the phospholipids is present in the coating of the lipid globules, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

2. The use according to claim 1, wherein improving cognitive performance or improving cognitive development is selected from improving: memory performance or memory development, learning ability, alertness, attention, language development, cognitive flexibility, inhibitory control, executive function, and concentration.

3. Use of lipids in the form of lipid globules for the preparation of nutritional compositions for the prevention and / or treatment of cognitive impairment associated with impaired meningeal fatty acid composition in human subjects, wherein... a. The lipid comprises at least 0.5% by weight of α-linolenic acid and at least 5% by weight of linoleic acid based on total fatty acids, and b. The lipid comprises at least 10% by weight palmitic acid based on total fatty acids, and at least 15% by weight palmitic acid is located at the sn-2 position of the triglyceride based on total palmitic acid. c. The lipid spheres have a mode diameter of at least 1 μm by volume and / or at least 45% by volume of the lipid spheres have a diameter of 2-12 μm, and d. The lipids comprise at least 0.5% by weight of phospholipids based on total lipids, wherein a portion of the phospholipids is present in the coating of the lipid globules, and The nutritional composition is not human milk, or the nutritional composition contains plant lipids.

4. The use according to claim 3, characterized in that, The purpose described is to prevent cognitive impairment.

5. The use according to claim 4, wherein the prevention of cognitive impairment is selected from the prevention of impairment in the following areas: memory performance or memory development, learning ability, alertness, attention, language development, cognitive flexibility, inhibitory control, executive function, and concentration.

6. The use according to claim 1 or 3, wherein the phospholipid comprises at least 5% by weight of sphingomyelin based on total phospholipids.

7. The use according to claim 1 or 3, wherein the nutritional composition comprises at least 0.1% by weight of docosahexaenoic acid based on total fatty acids.

8. The use according to claim 1 or 3, wherein the nutritional composition is given to an infant or young child aged 0 to 36 months.

9. The use according to claim 1 or 3, wherein, in later life, preferably at least one year after discontinuation of the nutritional composition, improvement in cognitive development and / or improvement in cognitive performance and / or prevention of cognitive impairment are achieved.

10. The use according to claim 1 or 3, wherein when the age of the human subject is greater than 36 months, improvement in cognitive development and / or improvement in cognitive performance and / or prevention of cognitive impairment is achieved.

11. The use according to claim 9 or 10, wherein a human subject is exposed to or raised in an obesity-inducing environment and / or consumes a Western diet high in fat and saturated fatty acids after infancy, wherein the fat provides more than 35% of the total dietary calories and wherein the saturated fatty acids provide more than 10% of the total dietary calories.

12. The use according to claim 1 or 3, wherein the amount of palmitic acid is 15 to 30% by weight based on total fatty acids, and 25 to 40% by weight of palmitic acid is located at the sn-2 position of the triglyceride.

13. The use according to claim 1 or 3, wherein the nutritional composition further comprises 10 to 50% by weight of lipids based on the dry weight of the nutritional composition, 9.6 to 12% by weight of protein based on the dry weight of the nutritional composition, and 20 to 80% by weight of digestible carbohydrates based on the dry weight of the nutritional composition, and optionally 0.25 to 20% by weight of indigestible oligosaccharides based on the dry weight of the nutritional composition.

14. The use according to claim 1 or 3, wherein the nutritional composition is an infant formula or subsequent infant formula or toddler formula.

Citation Information

Patent Citations

  • Human milk fat replacers from interesterified blends of triglycerides

    EP0698078A1

  • Corandomized fat compositions for infant formulas

    EP0758846A1

  • Mimetic lipids and dietary supplements comprising the same

    WO2005051091A1

  • Infant formulas for early brain development

    WO2008005033A1

  • Methods of maintaining or increasing growth or cognitive development

    WO2009051502A1